Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Liabilities and Shareholders Equity (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $276.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity changed N/A to $276.6 million in Q3 2025 year-over-year; TTM through Dec 2025 was $621.4 million, a 55.69% decrease, with the full-year FY2024 number at $396.9 million, down 22.49% from a year prior.
  • Liabilities and Shareholders Equity was $276.6 million for Q3 2025 at Pliant Therapeutics, down from $344.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $597.9 million in Q1 2023 to a low of $197.0 million in Q1 2022.
  • A 5-year average of $385.0 million and a median of $363.9 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 203.46% in 2023, then plummeted 33.9% in 2025.
  • Pliant Therapeutics' Liabilities and Shareholders Equity stood at $221.2 million in 2021, then soared by 58.49% to $350.6 million in 2022, then soared by 46.07% to $512.2 million in 2023, then dropped by 22.49% to $396.9 million in 2024, then plummeted by 30.32% to $276.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Liabilities and Shareholders Equity are $276.6 million (Q3 2025), $344.8 million (Q1 2025), and $396.9 million (Q4 2024).